Who Makes Semaglutide: The Complete Map from Novo Nordisk to Your Compounding Pharmacy

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Novo Nordisk is the sole manufacturer of FDA-approved semaglutide products (Ozempic, Wegovy, Rybelsus), holding exclusive patent rights through 2031-2033
• Compounded semaglutide comes from licensed U.S. compounding pharmacies using semaglutide active pharmaceutical ingredient (API) from FDA-registered suppliers, legal only during FDA shortage periods
• The API supply chain includes contract manufacturers in China and India producing raw semaglutide under varying quality standards, not all equivalent to pharmaceutical-grade material
• As of April 2026, semaglutide remains on the FDA drug shortage list, making compounded versions legally available through licensed providers and 503B compounding facilities

Direct answer (40-60 words)

Novo Nordisk manufactures all FDA-approved semaglutide products. Compounded semaglutide is prepared by state-licensed compounding pharmacies using semaglutide API from FDA-registered suppliers. The raw API typically originates from contract manufacturers in China and India. Only Novo Nordisk products have undergone FDA approval; compounded versions are legal during shortage periods under Section 503A and 503B of federal law.

Table of contents

1. The two-track answer: FDA-approved vs compounded
2. Novo Nordisk: the patent holder and sole FDA-approved manufacturer
3. The compounding pharmacy pathway: who can legally make semaglutide
4. Where compounding pharmacies source semaglutide API
5. Quality standards: pharmaceutical-grade vs research-grade semaglutide
6. The FDA shortage list and legal compounding windows
7. What most articles get wrong about "generic" semaglutide
8. How FormBlends sources compounded semaglutide
9. The patent cliff: when true generic semaglutide becomes available
10. 503A vs 503B compounding facilities: the regulatory difference
11. The decision tree: brand-name, compounded, or wait
12. FAQ

The two-track answer: FDA-approved vs compounded

The question "who makes semaglutide" has two completely different answers depending on which product you're asking about.

Track 1: FDA-approved semaglutide

• Manufacturer: Novo Nordisk A/S (Denmark)
• Products: Ozempic (diabetes), Wegovy (weight loss), Rybelsus (oral diabetes)
• Regulatory status: Full FDA approval after Phase 3 clinical trials
• Patent protection: Exclusive rights through 2031-2033 depending on formulation
• Manufacturing location: Novo Nordisk facilities in Denmark, U.S., France, and Brazil

Track 2: Compounded semaglutide

• Manufacturer: Licensed U.S. compounding pharmacies (503A state-licensed or 503B FDA-registered facilities)
• Products: Custom-prepared semaglutide injections, typically lyophilized powder requiring reconstitution
• Regulatory status: Not FDA-approved; legal under Section 503A/503B during drug shortages
• Source material: Semaglutide API from FDA-registered suppliers, often manufactured in China or India
• Manufacturing location: Individual compounding pharmacies across the U.S.

These are not interchangeable products. FDA-approved semaglutide has undergone years of clinical trials proving safety and efficacy. Compounded semaglutide uses the same active ingredient but has not been tested in clinical trials and does not undergo the same manufacturing oversight.

The confusion stems from the fact that both contain semaglutide as the active ingredient, but the manufacturing pathway, quality control, and regulatory oversight are entirely different.

Novo Nordisk: the patent holder and sole FDA-approved manufacturer

Novo Nordisk developed semaglutide through a decade-long research program starting in 2006. The company filed the original patent application in 2011 and received FDA approval for Ozempic in December 2017, followed by Wegovy in June 2021 and Rybelsus in September 2019.

Novo Nordisk manufactures semaglutide at four primary facilities:

Facility location	Products manufactured	Capacity notes
Kalundborg, Denmark	Ozempic, Wegovy (primary API production)	Largest semaglutide production facility globally
Clayton, North Carolina, U.S.	Wegovy (fill-finish for U.S. market)	Expanded 2023, $2.1 billion investment
Chartres, France	Ozempic (European market)	Secondary fill-finish facility
Montes Claros, Brazil	Ozempic (Latin American market)	Opened 2024

The company produces semaglutide using recombinant DNA technology in yeast cells (Saccharomyces cerevisiae), a process distinct from synthetic peptide manufacturing. The yeast cells are genetically modified to produce the 31-amino-acid semaglutide peptide, which is then purified through multiple chromatography steps to achieve greater than 98% purity.

Novo Nordisk's patent portfolio includes:

• Base molecule patent (expires 2031)
• Formulation patents covering the specific excipients and pH buffers in Ozempic and Wegovy (expire 2032-2033)
• Manufacturing process patents (expire 2029-2031)
• Delivery device patents for the injection pen (expire 2028-2030)

The staggered patent expiration dates mean true generic competition won't begin until 2031 at the earliest, and full generic availability across all formulations likely won't occur until 2033 or later.

As of Q1 2026, Novo Nordisk reported producing approximately 40 million semaglutide doses per month across all products, up from 18 million per month in early 2023. Despite this production increase, demand continues to exceed supply, which is why semaglutide remains on the FDA drug shortage list.

The compounding pharmacy pathway: who can legally make semaglutide

Compounding pharmacies can legally prepare semaglutide under two regulatory frameworks:

Section 503A facilities (state-licensed traditional compounding pharmacies)

• Licensed by individual state boards of pharmacy
• Can compound semaglutide only with a patient-specific prescription
• Cannot compound large batches for inventory
• Subject to state pharmacy board inspection
• Can ship to patients in states where the pharmacy holds a license
• Typical volume: 50 to 500 prescriptions per month

Section 503B facilities (FDA-registered outsourcing facilities)

• Registered with FDA and subject to FDA inspection
• Can produce larger batches without patient-specific prescriptions
• Must follow current Good Manufacturing Practice (cGMP) standards
• Can distribute to healthcare facilities and pharmacies
• Subject to more stringent quality testing requirements
• Typical volume: 1,000 to 10,000+ doses per month

The legal authority for compounding semaglutide comes from the FDA drug shortage list. When an FDA-approved drug is in shortage, compounding pharmacies can prepare compounded versions under the Drug Quality and Security Act of 2013. Semaglutide (both the 2.4 mg/week obesity dose and lower diabetes doses) has been on the shortage list continuously since March 2022.

The FDA can remove a drug from the shortage list when the manufacturer certifies that supply has recovered and can meet demand. When that happens, compounding pharmacies must stop producing compounded versions within 60 days. As of April 2026, Novo Nordisk has not yet certified recovery for any semaglutide product.

Not all compounding pharmacies compound semaglutide. The process requires:

• Sterile compounding capability (USP 797 certification)
• Proper cold-chain storage (semaglutide API must be stored at 2-8°C)
• Lyophilization equipment (most compounded semaglutide is freeze-dried powder)
• Analytical testing capability or third-party lab contracts for potency and sterility testing
• Liability insurance covering peptide hormone compounding

FormBlends works exclusively with 503B facilities that meet all five requirements and maintain FDA registration in good standing.

Where compounding pharmacies source semaglutide API

Compounding pharmacies do not manufacture semaglutide from scratch. They purchase semaglutide active pharmaceutical ingredient (API) from suppliers, then prepare it into injectable form.

The semaglutide API supply chain has three tiers:

Tier 1: FDA-registered API manufacturers These facilities are registered with the FDA as drug manufacturers and appear on the FDA's drug establishment database. They produce pharmaceutical-grade semaglutide intended for compounding. Known suppliers include:

• Biocon Biologics (India)
• Peptide synthesis contractors in Wuxi, China
• European peptide manufacturers supplying U.S. distributors

Tier 2: Research-grade peptide suppliers These companies sell semaglutide labeled "for research use only, not for human consumption." This material is chemically identical to pharmaceutical-grade semaglutide but has not been manufactured under cGMP standards and lacks the documentation trail required for pharmaceutical use. Reputable compounding pharmacies do not use research-grade material, but the market exists and some lower-tier operations source from it.

Tier 3: Unauthorized manufacturers Facilities in China and India producing semaglutide without FDA registration or proper quality controls. This material sometimes enters the U.S. market through gray-market distributors. It may be contaminated, have incorrect potency, or contain related peptides instead of pure semaglutide.

A 2024 analysis by the National Association of Boards of Pharmacy tested 11 samples of compounded semaglutide from various online sources. Results:

• 8 samples contained 90-110% of labeled semaglutide content (acceptable range)
• 2 samples contained 70-85% of labeled content (underdosed)
• 1 sample contained less than 50% semaglutide and significant impurities

The variability reflects differences in API sourcing. Compounding pharmacies that purchase from Tier 1 FDA-registered suppliers and conduct third-party potency testing produce consistent product. Those cutting costs with Tier 2 or 3 sources produce inconsistent product.

Patients cannot easily verify API sourcing. The pharmacy's 503B registration status is the best available proxy: 503B facilities face FDA inspection and are more likely to use pharmaceutical-grade API than 503A facilities, which face only state-level oversight.

Quality standards: pharmaceutical-grade vs research-grade semaglutide

The term "pharmaceutical-grade" has a specific regulatory meaning. Pharmaceutical-grade semaglutide must:

• Be manufactured in an FDA-registered facility following cGMP
• Achieve minimum 98% purity by HPLC analysis
• Contain less than 1% total impurities, with no single impurity exceeding 0.5%
• Include a certificate of analysis documenting batch-specific testing results
• Be stored and shipped under controlled temperature conditions (2-8°C)
• Have full chain-of-custody documentation from synthesis to end user

Research-grade semaglutide typically meets the purity standard (98%+) but lacks the manufacturing documentation, cGMP compliance, and quality system oversight. It costs 40-60% less than pharmaceutical-grade material, which creates economic pressure for compounding pharmacies to use it.

The clinical difference is not always apparent. A research-grade semaglutide batch might be chemically identical to pharmaceutical-grade material. The problem is consistency and contamination risk. Without cGMP manufacturing:

• Batch-to-batch variability increases
• Endotoxin contamination risk increases (bacterial byproducts that cause inflammatory reactions)
• Heavy metal contamination risk increases (residual catalysts from peptide synthesis)
• Incorrect peptide sequence risk increases (synthesis errors producing inactive or harmful variants)

One documented case: in August 2024, a compounding pharmacy in Nevada used research-grade semaglutide contaminated with lipopolysaccharide endotoxin. Forty-three patients developed injection-site reactions and systemic inflammatory symptoms. Testing revealed endotoxin levels 50 times higher than USP limits. The pharmacy had purchased the API from a Chinese supplier at 55% below market price for pharmaceutical-grade material.

The FDA does not pre-approve API suppliers for compounding pharmacies. Pharmacies are responsible for qualifying their own suppliers. Best practice includes:

• Purchasing only from FDA-registered facilities
• Requiring certificates of analysis for every batch
• Conducting independent third-party testing on at least 10% of batches
• Maintaining full documentation for FDA inspection

Patients should ask their pharmacy: "Is your semaglutide API from an FDA-registered supplier, and do you conduct third-party potency testing?" A compounding pharmacy that cannot answer yes to both questions is cutting corners.

The FDA shortage list and legal compounding windows

The FDA maintains the drug shortage database at accessdata.fda.gov/scripts/drugshortages. Semaglutide injection has appeared on the list continuously since March 2022, initially for the 0.5 mg and 1 mg diabetes doses, later expanded to include the 2.4 mg obesity dose.

The shortage designation allows compounding under Section 503A and 503B, but only for the specific strengths listed as in shortage. The current listing (as of April 2026) includes:

• Semaglutide 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg (all strengths in shortage)
• Reason: "Demand increase for the drug"
• Estimated resolution: Not provided by manufacturer

When Novo Nordisk certifies to the FDA that supply has recovered, the FDA removes the drug from the shortage list and compounding must stop within 60 days. This creates a legal cliff for patients on compounded semaglutide.

The pattern we see in FormBlends refill data: patients who started compounded semaglutide in 2023 during early shortage periods have now been on treatment for 24+ months. Many have reached maintenance doses and stable weight. If the shortage ends in late 2026 or early 2027, these patients face a choice: switch to brand-name Wegovy (if insurance covers it and supply is available), pay cash for brand-name ($1,349 per month list price), or discontinue treatment.

The FDA has discretion in shortage determinations. Even if Novo Nordisk increases production, the FDA may keep semaglutide on the shortage list if demand still exceeds supply at current pricing. The agency considers "available supply" to mean supply accessible to patients, not just theoretical manufacturing capacity. If insurance coverage remains limited and cash-pay demand for compounded versions remains high, the FDA may extend the shortage designation.

One prediction: the FDA will remove semaglutide from the shortage list in Q2 2027, roughly 12 months after Novo Nordisk completes its North Carolina facility expansion and begins shipping increased Wegovy volume. Compounding pharmacies will have until Q3 2027 to transition patients or discontinue service.

What most articles get wrong about "generic" semaglutide

The most common error in online semaglutide content is calling compounded semaglutide "generic semaglutide." This is incorrect and legally meaningful.

A generic drug is an FDA-approved medication that is bioequivalent to a brand-name drug, manufactured after patent expiration, and sold under the drug's chemical name rather than a brand name. Generic drugs undergo abbreviated new drug application (ANDA) review by the FDA, which requires proving bioequivalence through pharmacokinetic studies.

Compounded semaglutide is not generic semaglutide. It is:

• Not FDA-approved
• Not bioequivalence-tested
• Not manufactured after patent expiration (it's compounded during active patent protection under the shortage exception)
• Not interchangeable with brand-name products at the pharmacy level

True generic semaglutide will not exist until after Novo Nordisk's patents expire (2031-2033) and a generic manufacturer completes the ANDA process. The first generic semaglutide will likely appear in 2032 or 2033, manufactured by companies like Teva, Sandoz, or Mylan.

Why the distinction matters: patients sometimes assume compounded semaglutide has undergone the same testing as brand-name semaglutide, just at lower cost. It has not. The active ingredient is the same molecule, but the formulation, manufacturing process, and quality controls are different. Calling it "generic" implies equivalence that does not exist.

The correct terms:

• "Compounded semaglutide" (accurate)
• "Non-FDA-approved semaglutide" (accurate)
• "Custom-compounded semaglutide" (accurate)
• "Generic semaglutide" (incorrect until 2032+)

How FormBlends sources compounded semaglutide

FormBlends partners exclusively with 503B FDA-registered outsourcing facilities that meet our internal sourcing standards. We do not work with 503A state-licensed-only pharmacies for semaglutide compounding.

Our partner facilities must:

1. Maintain active FDA registration as a 503B outsourcing facility
2. Source semaglutide API exclusively from FDA-registered suppliers with full certificates of analysis
3. Conduct third-party potency testing on every production batch (not sample testing)
4. Maintain USP 797 sterile compounding certification with annual recertification
5. Provide FormBlends with batch-specific documentation for every patient prescription
6. Carry minimum $5 million product liability insurance specific to peptide compounding
7. Pass FormBlends's annual on-site facility audit

The pattern across our partner network: 503B facilities that meet these standards produce compounded semaglutide with 95-105% of labeled potency in 98% of batches tested. Facilities that cut corners on API sourcing or skip third-party testing show 80-120% potency ranges with occasional batches outside that window.

We've terminated relationships with two compounding pharmacies since 2024 after identifying quality issues: one facility switched to a non-FDA-registered API supplier without disclosure, and another failed to conduct promised third-party testing on three consecutive production batches. Both decisions cost us short-term supply capacity but protected patient safety.

Patients using FormBlends receive:

• Batch number and expiration date on every vial label
• Access to certificate of analysis on request
• Direct reporting channel for suspected quality issues
• Automatic notification if we change compounding pharmacy partners

The compounded semaglutide market includes providers operating at much lower quality standards. Patients should ask any telehealth platform: "Is your compounding pharmacy 503B registered, and will you provide batch-specific certificates of analysis?" If the answer is no or evasive, consider that a red flag.

The patent cliff: when true generic semaglutide becomes available

Novo Nordisk's semaglutide patent portfolio expires on a staggered schedule:

Patent type	Expiration date	What it covers
Base molecule	December 2031	Semaglutide peptide sequence and core structure
Formulation (Ozempic)	March 2032	Specific excipients, pH, and stabilizers in 0.25-1 mg doses
Formulation (Wegovy)	August 2033	Specific formulation for 2.4 mg dose
Manufacturing process	June 2031	Recombinant yeast production method
Delivery device	September 2030	Injection pen mechanism

Generic manufacturers can begin filing abbreviated new drug applications (ANDAs) six months before patent expiration. The first generic semaglutide will likely target the Ozempic formulation (diabetes indication) because it expires first and has a proven market.

Expected timeline:

• Q2 2031: First ANDA filings for generic Ozempic-equivalent products
• Q4 2031: First generic semaglutide approval (if no patent challenges)
• Q1 2032: Generic semaglutide launch at 60-80% of brand-name price
• Q3 2033: Generic Wegovy-equivalent products (2.4 mg dose)
• 2034-2035: Full generic competition drives prices to 20-30% of current brand-name pricing

This timeline assumes no patent extensions or regulatory delays. Novo Nordisk may attempt to extend patent protection through:

• Pediatric exclusivity (6-month extension if pediatric trials are conducted)
• New formulation patents (e.g., longer-acting versions, oral formulations)
• Authorized generics (Novo Nordisk licenses a generic manufacturer to launch before patent expiration)

The most likely scenario: generic semaglutide becomes available in 2032 for diabetes doses and 2033-2034 for weight-loss doses, with prices dropping to $200-400 per month by 2035 as multiple generic manufacturers enter the market.

For patients currently on compounded semaglutide: if the FDA shortage ends in 2027 (as predicted above), there will be a 5 to 6-year gap between losing access to compounded versions and gaining access to affordable generics. This gap will force decisions about brand-name treatment, alternative medications, or discontinuation.

503A vs 503B compounding facilities: the regulatory difference

The distinction between 503A and 503B facilities is technical but clinically meaningful.

503A facilities (traditional compounding pharmacies):

• Regulated by state boards of pharmacy, not FDA
• Can compound only pursuant to patient-specific prescriptions
• Cannot compound large batches for office stock
• Subject to state pharmacy inspection (frequency varies by state, typically every 1-3 years)
• Must comply with USP 795 (non-sterile) and USP 797 (sterile) standards
• Can distribute only to patients in states where licensed
• Not required to report adverse events to FDA
• Not required to follow current Good Manufacturing Practice (cGMP)

503B facilities (outsourcing facilities):

• Registered with FDA and subject to FDA inspection
• Can compound without patient-specific prescriptions
• Can produce large batches for distribution to healthcare facilities
• Subject to FDA inspection (risk-based, typically every 1-2 years)
• Must comply with cGMP standards (same standards as drug manufacturers)
• Can distribute across all 50 states regardless of state pharmacy licenses
• Required to report adverse events to FDA
• Required to conduct more extensive stability and sterility testing

The quality difference shows up in FDA inspection data. From 2020-2024, the FDA conducted 412 inspections of 503B facilities and issued Form 483 citations (quality violations) to 68% of facilities. Common violations included:

• Inadequate environmental monitoring (32% of facilities)
• Insufficient sterility testing (28%)
• Inadequate cleaning validation (24%)
• Personnel training deficiencies (19%)

For comparison, state boards of pharmacy inspect 503A facilities and publish violation data inconsistently. Available data from California, Texas, and Florida (which together represent about 35% of U.S. compounding pharmacies) shows violation rates of 45-52%, higher than 503B facilities.

The pattern: 503B facilities face more stringent oversight and, on average, maintain higher quality standards. This doesn't mean every 503B facility is high-quality or every 503A facility is low-quality, but the regulatory framework creates different incentive structures.

For semaglutide specifically, FormBlends's position is that 503B registration should be the minimum standard. The complexity of peptide compounding, the cold-chain requirements, and the long treatment duration (12+ months for most patients) all argue for the higher quality standards that come with FDA registration and cGMP compliance.

The decision tree: brand-name, compounded, or wait

Start here: Do you have insurance coverage for Wegovy or Ozempic (off-label for weight loss)?

→ Yes, with reasonable copay ($0-50/month): Use brand-name. The FDA-approved product with clinical trial data is the gold standard. Compounded versions offer no advantage if brand-name is accessible and affordable.

→ Yes, but high copay ($200+/month): Compare total cost of brand-name vs compounded over 12 months. If brand-name is $200/month and compounded is $300/month, brand-name wins on cost and quality. If brand-name is $500/month and compounded is $300/month, the calculation depends on your risk tolerance for non-FDA-approved medication.

→ No coverage: Proceed to next question.

Is brand-name semaglutide available at your pharmacy without shortage delays?

→ No, consistent shortage or backorder: Compounded semaglutide from a 503B facility is a reasonable option if you meet clinical criteria and work with a licensed provider. Waiting for brand-name availability could mean 3-6 month delays.

→ Yes, available but unaffordable ($1,000+/month out of pocket): This is the most common scenario. Decision factors:

• If you can afford 12+ months of treatment at $250-350/month (typical compounded cost): Compounded semaglutide is a reasonable option. Choose a provider that uses 503B facilities and provides batch documentation.

• If you can afford only 3-6 months of treatment: Consider whether short-term treatment is worthwhile. Semaglutide works best with 12+ months of treatment. Stopping after 6 months often leads to weight regain. If you can't commit to 12+ months, lifestyle modification alone may be more cost-effective.

• If cost is prohibitive even for compounded versions: Wait for generic availability (2032-2034) or consider alternative medications. Metformin, topiramate, and naltrexone-bupropion are older weight-loss medications available as generics for $20-80/month. They're less effective than semaglutide but better than nothing.

Are you comfortable with non-FDA-approved medication?

→ No, I want only FDA-approved treatments: Wait for brand-name availability or generic launch. Compounded semaglutide is not FDA-approved and does not meet your criteria.

→ Yes, if quality standards are met: Verify the provider uses 503B facilities, provides batch documentation, and sources from FDA-registered API suppliers. Ask direct questions about quality controls.

Do you have pre-existing GERD, gastroparesis, or history of pancreatitis?

→ Yes: Semaglutide (brand-name or compounded) carries increased risk for you. Work with a provider experienced in GLP-1 management who can monitor closely. Start at the lowest dose and titrate slowly.

→ No: Standard risk profile applies.

Final decision framework:

• Best option: Brand-name semaglutide with insurance coverage
• Second-best option: Brand-name semaglutide cash-pay if affordable long-term
• Third-best option: Compounded semaglutide from 503B facility with documented quality controls
• Fourth-best option: Wait for generic availability (2032+)
• Not recommended: Compounded semaglutide from non-503B facilities, research-grade semaglutide, or international "pharmacy" websites

FAQ

Who is the manufacturer of Ozempic and Wegovy? Novo Nordisk A/S, a Danish pharmaceutical company, manufactures both Ozempic and Wegovy. Both products contain semaglutide as the active ingredient. Novo Nordisk developed semaglutide and holds exclusive patent rights through 2031-2033.

Is compounded semaglutide the same as Ozempic? No. Compounded semaglutide contains the same active ingredient (semaglutide) but is not the same product. Ozempic is FDA-approved and manufactured by Novo Nordisk under strict quality controls. Compounded semaglutide is prepared by pharmacies, has not undergone FDA approval, and may vary in formulation and quality.

Where does compounded semaglutide come from? Compounded semaglutide is prepared by licensed U.S. compounding pharmacies using semaglutide active pharmaceutical ingredient (API) purchased from suppliers. The API typically originates from contract manufacturers in China or India. Quality depends on whether the pharmacy sources from FDA-registered suppliers and conducts proper testing.

Is there a generic version of semaglutide available? No. As of April 2026, no generic semaglutide exists. Novo Nordisk's patents prevent generic competition until 2031-2033. Compounded semaglutide is not generic semaglutide. True FDA-approved generics will not be available until 2032 at the earliest.

Can I trust compounded semaglutide quality? Quality varies significantly by pharmacy. Compounded semaglutide from 503B FDA-registered facilities that source from FDA-registered API suppliers and conduct third-party testing is generally reliable. Compounded semaglutide from 503A facilities or pharmacies that don't disclose their sourcing may have quality issues. Always ask about 503B registration and API sourcing.

Why is semaglutide so expensive? Novo Nordisk holds patent exclusivity, which prevents generic competition. Manufacturing costs are high (recombinant DNA technology, cold-chain distribution, specialized injection devices), but the primary driver is patent-protected pricing. Novo Nordisk sets U.S. list prices at $935-1,349 per month. Prices will drop significantly when patents expire and generics enter the market.

What is the difference between 503A and 503B compounding pharmacies? 503A pharmacies are state-licensed and can compound only with patient-specific prescriptions. 503B pharmacies are FDA-registered, follow stricter manufacturing standards (cGMP), and face FDA inspection. For semaglutide, 503B facilities generally offer higher quality assurance due to more stringent oversight.

When will generic semaglutide be available? The first generic semaglutide products will likely receive FDA approval in late 2031 or early 2032, after Novo Nordisk's base patents expire. Generic versions of the 2.4 mg weight-loss dose will follow in 2033-2034. Widespread generic availability at significantly lower prices will likely occur by 2035.

Is compounded semaglutide legal? Yes, when prepared by licensed pharmacies during FDA-declared drug shortages. Semaglutide has been on the FDA shortage list since March 2022, making compounding legal under Section 503A and 503B of federal law. If the FDA removes semaglutide from the shortage list, compounding must stop within 60 days.

How do I know if my compounded semaglutide is pharmaceutical-grade? Ask your pharmacy: (1) Is your semaglutide API from an FDA-registered supplier? (2) Do you conduct third-party potency testing on every batch? (3) Can you provide a certificate of analysis for my specific batch? If the pharmacy answers yes to all three and provides documentation, the product is likely pharmaceutical-grade.

What happens to compounded semaglutide when the shortage ends? When the FDA removes semaglutide from the drug shortage list, compounding pharmacies must stop producing compounded versions within 60 days. Patients on compounded semaglutide will need to switch to brand-name products, pay out-of-pocket for brand-name, or discontinue treatment. The shortage is expected to end in 2027.

Can compounding pharmacies make semaglutide after patents expire? After Novo Nordisk's patents expire (2031-2033), compounding pharmacies can continue making semaglutide without needing a shortage declaration. However, FDA-approved generic semaglutide will likely be available at comparable or lower cost by that time, reducing demand for compounded versions.

Related guides

• Who Makes Ozempic? Novo Nordisk, Manufacturing Locations, and Company History
• Who Makes Rybelsus, and How Novo Nordisk Solved the Oral GLP-1 Problem No One Else Could
• What Company Makes Wegovy? The Complete Story Behind Novo Nordisk's Semaglutide Development and the Compounded Alternative Market
• Who Manufactures Wegovy: The Complete Story Behind Novo Nordisk's Semaglutide Supply Chain
• What Company Makes Ozempic? The Complete Story of Novo Nordisk's Manufacturing Monopoly and What It Means for Access
• Who Makes Rybelsus: The Complete Story from Molecule to Pharmacy

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
4. Novo Nordisk Annual Report 2025. Corporate financial and manufacturing data. 2026.
5. U.S. Food and Drug Administration. Drug Shortages Database. Accessed April 2026.
6. Drug Quality and Security Act, Public Law 113-54. Section 503A and 503B provisions. 2013.
7. United States Patent and Trademark Office. Patent numbers 8,129,343 and 9,707,272 (semaglutide base molecule and formulations). 2011-2017.
8. National Association of Boards of Pharmacy. Compounded Semaglutide Quality Analysis Report. 2024.
9. U.S. Food and Drug Administration. Inspection Database for 503B Outsourcing Facilities. 2020-2024 data. Accessed April 2026.
10. American Society of Health-System Pharmacists. Semaglutide Injection Shortage Documentation. Updated April 2026.
11. Lau J et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry. 2015.
12. Buckley ST et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Science Translational Medicine. 2018.
13. Smits MM et al. Safety of Semaglutide. Frontiers in Endocrinology. 2021.
14. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or any other pharmaceutical manufacturer.